2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P4917A
    Somatostatin-14 (reduced) TFA 99.18%
    Somatostatin-14 (reduced) (SST 14) TFA is a polypeptide that can be found by peptide screening.
    Somatostatin-14 (reduced) TFA
  • HY-P99440
    Anumigilimab 2416593-08-1 98.43%
    Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation.
    Anumigilimab
  • HY-P99498
    Cergutuzumab amunaleukin 1509916-03-3 99.5%
    Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities.
    Cergutuzumab amunaleukin
  • HY-P99563
    Tibulizumab 1849636-24-3 98.86%
    Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research.
    Tibulizumab
  • HY-P99884
    Sasanlimab 2206792-50-7 99.75%
    Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma.
    Sasanlimab
  • HY-U00190
    Deprodone propionate 20424-00-4 99.62%
    Deprodone propionate (RD20000) is a corticosteroid which is obtained by esterifying with propionic acid the 17-position of the prednisolone skeleton and deoxidating its 21-position.
    Deprodone propionate
  • HY-Y0344I
    Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al 7647-14-5 99.99%
    Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt is an orally active salt. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the expression of ATP1A1. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt drives autoimmune disease by the induction of pathogenic Th17 cells.
    Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al
  • HY-100210A
    FN-439 TFA 99.65%
    FN-439 TFA is a selective collagenase-1 inhibitor. FN-439 TFA inhibits collagenase-1 with an IC50 value of 1 μM. FN-439 TFA can be used for the research of cancer and inflammation.
    FN-439 TFA
  • HY-100754C
    Ritlecitinib tosylate 2192215-81-7 99.65%
    Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).
    Ritlecitinib tosylate
  • HY-112318A
    GSK-2793660 1613458-78-8 99.91%
    GSK-2793660 is an orally active and irreversible inhibitor of Cathepsin C (CTSC). GSK-2793660 can be used for the research of bronchiectasis.
    GSK-2793660
  • HY-116374S
    Glycolithocholic acid-d4 2044276-16-4 99.37%
    Glycolithocholic acid-d4 is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
    Glycolithocholic acid-d4
  • HY-119674A
    Xanthopterin hydrate 5979-01-1 98.0%
    Xanthopterin hydrate, an unconjugated pteridine compound, is the main component of the yellow granule in the Oriental hornet bear wings, produces a characteristic excitation/emission maximum at 386/456 nm. Xanthopterin hydrate(XPT) causes renal growth and hypertrophy in rat. Xanthopterin hydrate inhibits RNA synthesis.
    Xanthopterin hydrate
  • HY-125527S
    Resolvin D1-d5 1881277-32-2 99.2%
    Resolvin D1-d5 is the deuterium labeled Resolvin D1. Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α-mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages.
    Resolvin D1-d5
  • HY-127029A
    Umbelliprenin 23838-17-7 99.93%
    Umbelliprenin, a prenylated coumarin, is an antioxidant with anticancer, anti-inflammatory and immunomodulatory effects. Umbelliprenin inhibits lipoxygenase managing the inflammation pathways. In inflammatory macrophages, Umbelliprenin suppresses nitric oxide production as well as inducible nitric oxide synthase (NO synthase).
    Umbelliprenin
  • HY-128749A
    D-Glucaric acid tetrahydrate 5793-89-5 ≥98.0%
    D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases.
    D-Glucaric acid tetrahydrate
  • HY-128945A
    CL2A TFA 99.87%
    CL2A TFA is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A TFA is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker.
    CL2A TFA
  • HY-130138C
    5,6-DiHETE 845673-97-4
    5,6-DiHETE is an anti-inflammatory lipid mediator derived from eicosapentaenoic acid (EPA). 5,6-DiHETE has the ability to suppress vascular hyperpermeability during inflammation and is used in the research of inflammatory diseases.
    5,6-DiHETE
  • HY-138139A
    AXC-715 hydrochloride 2490497-93-1 99.89%
    AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist. AXC-715 can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants.
    AXC-715 hydrochloride
  • HY-139907B
    DG013A formate 99.57%
    DG013A (formate) is a phosphinic acid tripeptide mimetic inhibitor. DG013A (formate) displays significantly weak affinity for both ERAP1 (IC50=33 nM) and ERAP2 (IC50=11 nM). DG013A (formate) can be used for the research of autoimmune disease and cancer.
    DG013A formate
  • HY-15027S1
    5-Aminosalicylic acid-d3 1309283-32-6 99.38%
    5-Aminosalicylic acid-d3 is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
    5-Aminosalicylic acid-d3
Cat. No. Product Name / Synonyms Application Reactivity